|
Jul 16
|
Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum
|
|
Jul 15
|
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
|
|
Jul 2
|
Invitation: Sobi's Q2 report
|
|
Jul 1
|
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
|
|
Jun 27
|
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
|
|
Jun 6
|
Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases
|
|
Jun 6
|
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
|
|
Jun 4
|
Sobi Showcases Breadth of data in C3G/primary IC-MPGN at ERA 2025
|
|
Jun 3
|
Invitation: Sobi's Aspaveli® - 52-week Phase 3 VALIANT data in nephrology
|
|
Apr 15
|
Invitation: Sobi's Q1 report
|
|
Apr 1
|
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
|
|
Mar 31
|
Sobi publishes Annual and sustainability report for 2024
|
|
Feb 20
|
EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN
|
|
Feb 20
|
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
|